GREENWICH, Conn., Dec. 2, 2013 /CNW/ - Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company's senior management leadership team.
Dr. Goldman will focus his efforts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after achieving significant success at ICON Clinical Research, a leading global Contract Research Organization that specializes in the provision of clinical and other solutions that support Phase I-IV clinical studies.
Dr. Goldman stated, "I'm delighted to join Aptuit, and look forward to working closely with the entire team to leverage an outstanding value proposition that is unique in our industry. Pharma has an unmet need for lower cost, increased speed and better quality in drug discovery and development. Aptuit is the ideal partner to meet these needs across a comprehensive suite of services, supported by an approach that is both scientific and innovative. I look forward to continued growth of the company as the partner of choice for drug developers."
At ICON, Dr. Goldman was most recently Executive Vice President, Global Strategic and Business Development and a member of the senior leadership team. His accomplishments included record growth levels of sales, and the development of transformative business relationships with leading pharmaceutical and biotechnology companies. Previously, his roles at ICON included Executive Vice President, Operations, Strategic Programs and Chief Medical Officer, ICON Medical Imaging.
Before joining ICON, Dr. Goldman served for 7 years as the Chief Medical Officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held honorary academic positions of increasing responsibility at the University of California since 2000, most recently as Associate Clinical Professor of Medicine in the Division of Cardiology. He holds a medical degree from St. Bartholomew's Hospital Medical College, University of London, and MBA degrees from Columbia University in New York, and the University of California, Berkeley.
Mr. Tyson commented, "We're enthusiastic that Jonathan is joining us. He brings exceptional experience in science, sales and medicine, along with the innate talents that are needed to advance us to the next level of growth and accomplishments. His collaborative approach to understanding and satisfying the unmet needs of our clients makes him the perfect complement to our senior management team."
Stuart Needleman, Aptuit's President and Chief Operating Officer, added, "Over the past few years, we have achieved an impressive track record of success in delivering drug discovery and development results in multiple therapeutic areas. I am especially proud of recent results we have delivered, since they enabled our clients to succeed despite some very difficult circumstances. Aptuit continues to forge ahead on a serious path of aggressive growth, and Jonathan is an industry leader who can help us to get to the next level through his focus on top line opportunities."
Aptuit LLC provides the most complete set of integrated early to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, and Pharmaceutical Sciences. The company maintains five global facilities with approximately 800 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.
For more information about Aptuit, visit www.aptuit.com
For further information: